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Abstract
Although the incidence of dementia increases exponentially with age, some individuals reach more than 100 years with
fully retained cognitive abilities. To identify the characteristics associated with the escape or delay of cognitive decline, we
initiated the 100-plus Study (www.100plus.nl). The 100-plus Study is an on-going prospective cohort study of Dutch
centenarians who self-reported to be cognitively healthy, their first-degree family members and their respective partners.
We collect demographics, life history, medical history, genealogy, neuropsychological data and blood samples. Cente-
narians are followed annually until death. PET–MRI scans and feces donation are optional. Almost 30% of the centenarians
agreed to post-mortem brain donation. To date (September 2018), 332 centenarians were included in the study. We
analyzed demographic statistics of the first 300 centenarians (25% males) included in the cohort. Centenarians came from
higher socio-economic classes and had higher levels of education compared to their birth cohort; alcohol consumption of
centenarians was similar, and most males smoked during their lifetime. At baseline, the centenarians had a median MMSE
score of 25 points (IQR 22.0–27.5); most centenarians lived independently, retained hearing and vision abilities and were
independently mobile. Mortality was associated with cognitive functioning: centenarians with a baseline MMSE score
C 26 points had a mortality percentage of 17% per annual year in the second year after baseline, while centenarians with a
baseline MMSE score\26 points had a mortality of 42% per annual year (p = 0.003). The cohort was 2.1-fold enriched
with the neuroprotective APOE-e2 allele relative to 60–80 year-old population controls (p = 4.8 9 10-7), APOE-e3 was
unchanged and the APOE-e4 allele was 2.3-fold depleted (p = 6.3 9 10-7). Comprehensive characterization of the
100-plus cohort of cognitively healthy centenarians might reveal protective factors that explain the physiology of long-term
preserved cognitive health.
Keywords 100-plus Study  Prospective cohort study  Centenarians  Cognitive health longevity
Background
Although increasing age is the strongest risk indicator for
cognitive decline and dementia, it is not an
inevitable consequence of aging. The incidence of overall
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dementia starts to increase exponentially from approxi-
mately 60 years and at age 100 years the annual dementia
incidence reaches 40% per year [1, 2]. However, the mere
existence of cognitively healthy individuals older than
110 years [3–6] leads to the intriguing suggestion that the
incidence of dementia decelerates somewhere after
100 years (see Box). Factors that allow for the preservation
of cognitive health may thus be enriched for in super-agers,
individuals who reach extreme ages with full cognitive
functions [7]. The combination of extreme old age with
maintained cognitive health is often observed in families
[8–13], suggesting that beneficial factors involved in the
long-term maintenance of both cognitive and overall health
are heritable, and likely genetic [7, 14–16]. Indeed, results
from the New England Centenarian Study indicated that
siblings from centenarians are* 8–12 times more likely to
reach 100 years compared to individuals with no cente-
narian siblings [17].
This raises several questions: what are the unique
molecular mechanisms that cause resilience against age
related decline? Which hereditable factors are involved,
and what is the role of the immune system? The answers to
these questions are likely to provide novel insights in the
effects of aging on the brain and they will be informative
for the design of novel strategies that intervene in processes
that lead to neurodegenerative diseases [18]. Answers to
these questions might be found in the context of prospec-
tive follow-up studies, however, this is complicated by the
fact that only * 0.6% of the population born in the early
1900s reaches 100 years (see Box). Therefore, we set out to
identify protective factors in a cohort of centenarians who
self reported to be cognitively healthy. For this, we initi-
ated the 100-plus Study in 2013 at the Alzheimer Cen-
ter Amsterdam in the Netherlands (www.100plus.nl). To
date, the cohort includes 332 centenarians.
Children of centenarians also profit from the advantage
they inherited from their centenarian parent: they live
longer, and they have almost a 90% lower risk of devel-
oping myocardial infarction, stroke and diabetes compared
to age-matched peers whose parents have average life
spans [15, 19, 20]. Together, this suggests that first-degree
family-members of centenarians are also enriched for
protective (genetic) factors and that efforts to identify
protective factors should include targeting the families of
centenarians [21]. The value of using by-proxy phenotypes
for genetic studies was recently demonstrated for 12 dis-
eases [22], and recently for Alzheimer’s Disease [23, 24].
Centenarian children represent the by-proxy phenotype of
extreme longevity which allows the opportunity to com-
pare the composition of biomaterials or other features rel-
ative to age-matched controls [25]. For this reason, we
extended the 100-plus Study with a second phase in 2017,
in which we also include first-degree family-members of
centenarians and their partners.
The 100-plus Study has a main focus on the biomolec-
ular aspect of preserved cognitive health. It is beneficial
that cohort inclusion is on-going, as this allows us to take
optimal advantage of the recent developments in high-
throughput biomolecular techniques. For example, genetic
variants of interest can be functionally tested in our col-
lection of fresh blood samples and brain tissues from
carriers.
Here we present the rationale for the 100-plus Study (see
Box), we describe the study design and procedures, and we
introduce the 100-plus Study cohort based on the clinical
presentation of the centenarians at baseline, and the
demographic characteristics of the centenarians relative to
their birth cohort.
Methods/study design
Please find in the electronic supplementary material
(ESM.pdf) a complete compendium of participant inclu-
sion procedures and current data collection procedures of
the 100-plus Study.
Inclusion and exclusion criteria
The 100-plus Study includes (1) Dutch-speaking cente-
narians who can (2) provide official evidence for being
aged 100 years or older, (3) self-report to be cognitively
healthy, which is confirmed by an informant (i.e. a child or
close relation), (4) consent to donation of a blood sample
and (5) consent to (at least) two home-visits from a
researcher, which includes an interview and neuropsycho-
logical testing. In the second phase of the 100-plus Study
(from September 2017 onwards) we include (1) siblings or
children from centenarians who participate in the 100-plus
Study, or partners thereof who (2) agree to donate a blood
sample, (3) agree to fill in a family history, lifestyle history
and disease history questionnaire. Study exclusion criteria
are limited to subjects who are legally incapable.
Recruitment and research visits
Recruitment
We regularly perform an online search for local newspaper
articles that mention a centenarian. These reports com-
monly include the name of the centenarian, and sometimes
a description of their well-being and living situation. We
retrieve an address online and we approach a prospective
study participant by letter. When they express their interest
in study participation and inclusion criteria are met, we
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schedule two baseline visits. (See ESM.pdf for detailed
recruitment procedures).
Baseline visit
A researcher, trained to perform standardized visit proce-
dures, will visit the centenarian. The baseline visit (T0)
consists of two visits. The first baseline visit takes
approximately 2 to 3 h, and comprises obtaining informed
consent for study inclusion, a life-history interview, an
assessment of genealogy, and an assessment of current
health and medical history (Table 1). The second baseline
visit, approximately 1 week after the first, takes approxi-
mately 1.5 h: during this visit we subject the centenarian to
a battery of neuropsychological tests and we measure grip
strength and blood pressure (Table 2). During the first
baseline visit we inform participants of optional parts of the
100-plus Study: feces collection, PET–MRI or PET–CT
imaging and post-mortem brain donation (Fig. 1). Once a
centenarian volunteers to participate in these parts of the
100-plus Study, we obtain informed consent for these study
parts separately.
Follow-up visits
During yearly follow-up visits (T1, T2, …), which take
approximately 2 h, we inform about possible changes in
cognitive functioning that took place in the last year, we
update the interview questionnaire and re-administer the
complete cognitive test battery and physical measurements
(Tables 1, 2). Follow-up is continued until the participant
is no longer willing/able to participate. When the MMSE
score declines B 20 there is evidence of clear cognitive
impairment [26], and subjecting a centenarian to a neu-
ropsychological testing battery becomes more complicated
and follow-up visits by a researcher may no longer be
constructive. When the MMSE at last visit drops below 20
(imputed MMSE score), we follow-up by informant ques-
tionnaire. To ensure up-to-date cognitive health measure-
ments of brain donors, we administer telephone an
informant questionnaires 6 months after the annual visit
(T0.5, T1.5, …). For a diagram of procedures see Fig. 2.
We ask informants to inform us when a participant dies and
about the events that preceded death.
Data collection
Centenarian presentation
During each visit, the researcher subjectively estimates the
visual, hearing and mobility function as ‘‘good’’, ‘‘moder-
ate’’, ‘‘poor’’ or ‘‘very poor’’, according to the determinants
listed in Table 3. We collect the following variables
regarding centenarian presentation: the level of indepen-
dence during activities of daily living (ADL) using the
Barthel Index [27], an estimation of the total hours of care/
assistance needed per week; category housing situation,
(independent-dependent); grip strength, systolic and dias-
tolic blood pressure; heartbeat; and napping habits and
sleep quality (Pittsburg Sleep Quality Index questionnaire
[28]). We assess whether the centenarian suffers from
symptoms of depression [29] by administering the 15-item
geriatric depression scale (GDS-15). We ask about recent
weight loss, current weight and length and whether the
centenarian has active infections.
Medical history
From the General Practitioner (GP) of the centenarian, we
request a summary report of the diagnosed conditions and
prescribed medications. These conditions are categorized
by a GP dedicated to the 100-plus Study (Table 4). After
a centenarian dies, we request a second synopsis from the
GP, describing the medical proceedings until death. In a
self-report medical history questionnaire, we inquire about
blood pressure, heart disease; stroke (CVA) or TIA;
tumors, head injuries, incontinence, dental condition,
mental health problems, hospital visits, surgeries/anesthe-
sia. We estimate BMI at midlife by recording self-reported
weight and length at middle-age (* 50 years). For cente-
narian-females we inquire about age at menarche, onset of
menopause, number of pregnancies and/or miscarriages.
Cognitive profiling
We objectively evaluate cognitive functioning using a
comprehensive neuropsychological test battery that
addresses memory, attention and/or concentration, pre-
morbid intelligence, language, executive and visuo-spatial
functions (Table 2). To assess overall cognitive function-
ing we administer the Mini–Mental State Examination
(MMSE) [26]. Geriatric sensory impairments such as bad
eyesight or bad hearing complicated performance, which
led to missing items. MMSE scores with different missing
items cannot be directly compared, because the total
obtainable score is different per centenarian. Therefore, we
adjust scores using multiple imputation (see ‘MMSE
imputation’ in ESM.pdf). In addition, at every visit the
researcher subjectively estimated cognitive functioning of
the centenarian (for procedures see ESM.pdf). During each
research visit we ask an informant to fill in the Dutch
version of the abbreviated form of the Informant Ques-
tionnaire on Cognitive Decline (IQ-CODE) to indicate
whether the centenarians experienced cognitive decline in
the past 10 years (or, in case of follow-up visits, during the
past year) [30, 31].
The 100-plus Study of cognitively healthy centenarians: rationale, design and cohort… 1231
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Table 1 Overview of 100-plus Study data-collection
Study participants Actions
Centenarians First baseline visit: interview
Phase 1 and Phase 2 Formalities for study inclusion: ICF; Proof of age
Childhood living environment; Education; Marriage/Partners; Number of children, Religion, Occupation; Occupation
of parents and partner
Genealogy of first degree family members and partners; Disease history in family
Lifestyle Questionnaire: Smoking habits; Drinking habits; Lifetime cognitive activity scale; situation during WWII
Disease history (self-report): weight/length; incontinence; medication intake, dental condition (stopped); hospital visits/
anesthesia
Researcher subjective estimate of sight, hearing, mobility, cognitive status;
Centenarian presentation: current housing situation, total hours of care; ADL (Barthel index); sleep quality (PSQI);
Geriatric Depression Scale (GDS); cognitive well-being judged by informant (IQ-CODE)
Collection of biomaterials and biomarkers: blood sampleab
Second baseline visit
Neuropsychological test battery: Table 2
Measurement of grip strengthb and blood pressureb
Follow up
MMSE at last visit[ 20: yearly visit: update of general well-being, disease history, and missed items at baseline
interview; Researcher subjective estimate of sight, hearing, mobility, cognitive status;
Neuropsychological testing battery (Table 2) Barthel index; GDS; IQ-CODE, grip strength measurementb; blood
pressure measurementb
MMSE at last visit B 20; phone interview: update of general well-being, disease history, and missed items at baseline
interview; IQ-CODE (by mail), ADL (Barthel index)
For brain donors: half yearly follow-up: TICs-M (by telephone); IQ-CODE (by mail)
GP
At baseline inclusion: request for summary of medical events
Post mortem: request medical events leading to death
Optional in Phase-2
MRI-PET or PET-CT scan
Feces donation
iPS cell generation
Post mortem brain donation
Centenarian children and partners
Phase-2
Baseline visit
Formalities for study inclusion: ICF
Collection of blood sampleb









Update lifestyle questionnaire, current health, disease history and general well-being Blood sample, MMSE, Barthel
index; IQ-CODE; grip strengthb and blood pressure measurement,b estimation of sight, hearing, and mobility;
Researcher subjective estimate of sight, hearing, mobility, cognitive status;
Mail: questionnaire on lifestyle, general well-being, education and occupation, disease history, and genealogy
Follow up
Yearly: TICs-M (by telephone); IQ-CODE (by mail)
GP
For specific cases: request for summary of medical events
aBlood sample collection may occur at a different occasion, close to first baseline visit; Phase-2 of the 100-plus Study started in September 2017
bBlood sample biomarkers determined in the blood sample, assessment of blood pressure and measurement of grip strength are described in detail
in ESM.pdf. TICS-M: Telephone Interview Cognitive Status—Modified (see Table 2); IQ-COde Informant Questionnaire on Cognitive Decline
in the elderly short form (see Table 2)
1232 H. Holstege et al.
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Lifetime/demographic characteristics
To investigate the family genealogy and disease occur-
rence, we draw a pedigree including children, siblings,
parents and grandparents, their (maiden) names, gender,
birth years, age at death and cause of death, occurrence of
dementia/cognitive decline (Fig. 3). To determine socio-
economic background (SEB) and socioeconomic status
(SES) we inquire about the main occupation of the father
and mother of the centenarian, the main occupation of the
centenarian him/herself at adulthood and the main occu-
pation of their partner(s). We inquire about the education
level and the number of years education was followed.
Education levels were classified according to (I) ISCED
1997 [32] and according to the classification system used
in the Dutch 1971 census [33].
Lifetime habits
We address smoking habits and alcohol consumption
(see ESM.pdf). We administer the Cognitive Activity
Questionnaire (CAQ) [34, 35] to investigate cognitive
stimulating experience during adult life (from childhood to
50 years) and current cognitively stimulating experience.
Table 2 Neuropsychological tests and questionnaires
Domain or goal Assessment/questionnaires Duration
(min)
Cognitive functioning
Overall cognitive functioning Researcher subjective impression of cognitive health (see ‘‘Methods’’) 0
Mini–Mental State Examination [26, 86] 5
National Adult Reading Testa [88–89] 3
Telephone Interview Cognitive Status—Modified (TICS-M)d [90]
Memory CERAD 10-word list—immediate and delayed recall [91] 15
Visual Association Test—Memory [92] 5
Rivermead Behavioral Memory Test (RBMT)b immediate and delayed recall [93, 94] 6
Attention Digit Span—forwards [96–97] 3
Trail Making Test A [98, 99] NA
Executive functions Digit Span—backwards [96–97] 3
Letter Fluency—DAT [101–104] 2
BADS—subtest Key Search [105, 106] 3
BADS—subtest Rule Shift Cards [105, 106] 3
Trail Making Test B [98, 99] 10
Amsterdam Dementia Screening Test—Meander figure [107] 2
Language Category Fluency—Animals [100, 101, 108] 2
Visual Association Test—Naming [92] 1
Visuo-spatial functioning/construction CAMDEX-R/N CAMCOG—figure copying [109, 110] 3
Clock Drawing Test [111, 112] 2
Visual Object and Space Perception (VOSP) Batteryb—subtest Number Location
[113]
3
Depression, ADL, sleep, lifestyle, geriatric impairments
Depressive symptoms Geriatric Depression Scale-15 (GDS) [29] 4
(Instrumental) Activities of daily living Informant Questionnaire on Cognitive Decline in the elderly short form (IQ-CODE)
[30, 31]
3
Barthel Index [27, 115–116] 3
Lifetime cognitively stimulating
experience
Lifetime Cognitive Activity Scalea [34, 35] 5
Sleep quality Pittsburgh Sleep Quality Indexa (PSQI) [28] 5
Geriatric impairments Researcher subjective impression of sight, hearing, mobility (‘‘Methods’’) 0
aOnly administered at baseline, b In 100-plus Study-phase 1 only, c Included with the confirmation letter of study-inclusion, collected during the
first baseline visit, d Only administered during half yearly-follow up of brain donors and yearly follow-up of siblings
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Data-collection of first degree living centenarian-relatives
and partners
For centenarian siblings and their partners, we administer
the MMSE at the study inclusion visit and we record the
genealogy at the level of the centenarian-genera-
tion (Fig. 3). We will yearly monitor changes in physical
well-being and in cognitive health using TICS-M and IQ-
Code-N. We ask centenarian-children and partners to fill in
an abbreviated version of the centenarian questionnaire; we
record the genealogy of the centenarian-generation, no
cognitive testing will be administered; we will not follow-
up centenarian-children and their partners (Table 1).
Biomaterials
Biomaterial collection
We collect a blood sample from centenarians and their
family members for DNA isolation, peripheral blood
mononuclear cells (PBMCs), plasma, serum, and when
consent is given for generation of induced pluripotent stem
cells (iPSCs) (Fig. 3). DNA samples are currently used for
APOE genotyping, GWAS, whole exome sequencing
(WES) and Sanger sequencing. Furthermore, all centenar-
ians are informed about the option for feces donation for
gut microbiome analysis, PET–MRI or PET–CT brain
scans for in vivo detection of amyloid beta presence and
structural brain imaging. We also inform about the option
of post-mortem brain donation. Brain autopsies are
performed in collaboration with the Netherlands Brain
Bank [36, 37]. For numbers of collected biomaterials thus
far, please see additional data (ESM.pdf).
Data storage
OpenClinica open source software (version 3.1 onwards) is
used for data management [38]. Biomaterials are stored in
the biobank of the Amsterdam UMC.
Cohort description
Included centenarians
Between January 1st 2013 and September 1st 2018, 332
centenarians were included in the study of whom almost
30% (n = 92) agreed to post mortem brain donation. Thus
far, 58 centenarians have come to autopsy. On June 21st
2017, 764 centenarians were approached for study-partic-
ipation of which 300 (40%) met study-inclusion criteria
and were included in the study (Fig. 4). Here, we describe
the cohort using the collected data from these first 300
centenarians. For all cohort descriptives see Table 5.
The mean age at inclusion of centenarians was
101.3 ± 1.7 years (ESM.pdf Fig S1A). The majority of
centenarians were born between 1910 and 1917 (ESM.pdf
Fig S1B). Of the 300 centenarians in the cohort, 284 were
born in a Dutch municipality, 6 were born in the Dutch
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Fig. 1 Overview of the 100-plus Study, Phase 2: During home visits
we inquire about life-history of the centenarians, their family history,
medical history, and current health. We assess their performance on
neuropsychological tests, measure blood pressure and grip strength
and we collect a blood sample, for blood testing and genetic analyses.
Optional parts of the study are: a visit to the outpatient clinic for
PET–MRI and/or PET–CT imaging, feces donation to investigate the
gut microbiome, and the generation of iPS cells from peripheral
blood. Furthermore, all participants are informed about the option of
post-mortem brain donation in collaboration with the Netherlands
Brain Bank [37]. This is optional and not required for study
participation. We evaluate changes in general well-being and in
neuropsychological test performance during (half-)yearly follow-up
visits. Next to the centenarians, we also include their first-degree
family members and their partners. *Collected in Phase-2 of the
100-plus Study, started in September 2017
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centenarians were born in other European countries. Cen-
tenarian birth-municipalities indicated that the catchment
area is spread across the 11 provinces of the Netherlands in
the early 1900’s (ESM.pdf Fig S2).
Presentation at baseline
Subjective researcher estimates of geriatric sensory
impairments indicated that 87% of the centenarians had
moderate-good hearing abilities (ESM.pdf Fig S3A), that
77% of the centenarians had moderate-good vision
(ESM.pdf Fig S3B), and that 80% of the centenarians were
independently mobile (ESM.pdf Fig S3C). The majority
(52%) of the centenarians in the cohort lived independently
(i.e. community dwelling without assistance, or indepen-
dent in a residence with available services), 42% lived in
private quarters in a residential care center, while only
1.7% of the centenarians lived in a nursing home (ESM.pdf
Fig S3D). Centenarians scored a median of 15 points (IQR
12–18), on the Barthel index: 45% of the centenarians
scored between 15 and 19, which indicates a need for
minimum help with activities of daily living (ADL), while
32% scored 20 points which indicates they are fully inde-
pendent in ADL (ESM.pdf Fig S3E). The centenarians in
the cohort have no or very few symptoms of depression:
they scored a median of 2 points on the 15-items version of
Obtaining informed consent
Disease and lifestyle history (Table1) 
Family/genetic assessment 
Blood pressure measurement 
Grip strength measurement 
Blood sample collection
Inform about brain donation (optional) 
Inform about MRI/PET scans (optional2)
Inform feces donation (optional2)  





Brain imaging (MRI-PET) 
Visit to Vumc
Study information 




Interest for study inclusion 
3 hrs
15 min 
Siblings and Partners: 
• Blood sample collection 
• MMSE
• Questionnaire
• Yearly follow-up (telephone)
Children and Partners: 
• Blood sample collection 
• Questionnaire
• No follow-up 










Fig. 2 Diagram of visit procedures of 100-plus Study: 1Half yearly
follow-up by telephone is performed for centenarians who agreed to
brain donation. 2Collected in phase-2 of the 100-plus Study, started in
September 2017. 3Data from centenarian-children and children in-
laws will be obtained during the visit with the centenarian
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the Geriatric Depression Scale (IQR 1–3), and scores\ 5
indicate no evidence for depression [29] (ESM.pdf Fig
S3F).
Disease prevalence and multi-morbidities
In June 2017 we had received GP reports from 209 cen-
tenarians, and categorized diagnosed conditions (Table 4).
At baseline, centenarians were diagnosed with or had
symptoms of on average 3.7 ± 1.5 morbidities (ESM.pdf
Fig S3G). Cardiovascular problems are the most common
condition in centenarians (83.7% has at least one mention
of a cardiovascular condition in their GP report). And
hypertension is mentioned in the GP reports of almost half
of all centenarians. Removal of hypertension from the list
of cardiovascular conditions still leaves 66.5% of the
centenarians with at least one mention of a cardiovascular
condition (Table 4). Musculoskeletal disease and hyper-
tension were more prevalent in females (72 vs. 39% and 54
vs. 34%), while cardiovascular conditions were more
prevalent in males (77 vs. 63%). Most aging-associated
diseases were first mentioned in the GP report when the
centenarian was[ 90 years old, suggesting a seemingly
high age at onset. As we cannot correct for methodological
differences in data collection by GPs, we were not able to
perform a systematic comparison with disease incidence
statistics from prospective cohort studies (for further
explanation see ‘age at disease onset’ analysis in
ESM.pdf).
Cognitive function (Mini Mental State
Examination, MMSE)
At cohort inclusion, the average raw MMSE score was
23.9 ± 4.4 points. We adjusted for missing items due to
hearing or vision impairments, which allowed us to directly
compare MMSE scores between centenarians (see Meth-
ods). At study inclusion the average adjusted MMSE score
of the 100-plus Study cohort was 24.3 ± 4.23 points
(median score 25, IQR 22.0–27.5) (Fig. 5a). For 287 cen-
tenarians, a trained researcher estimated cognitive health.
The large majority (83%) of the centenarians was subjec-
tively estimated to be cognitively healthy, and this group
scored a median of 26 points on the MMSE (IQR 23.5–28).
This was significantly higher than the median MMSE score
of 19 (IQR 16.4–22) by the 41 centenarians for whom
cognitive health was ‘‘doubted’’ (p = 4 9 10-3, two-tailed
t test with unequal variance), and the median MMSE score
of 8 centenarians who were estimated to have ‘‘probable
cognitive impairment’’ was 16.4, (IQR 12.8–17) (Fig. 5b).
MMSE and mortality rates
The mortality percentage (presented per annual-year)
underestimates the mortality at extreme ages, such that we
prefer presenting the instant mortality rates (presented per
life-year); for rationale and calculation procedures see
ESM.pdf. Within the group of 293 participants for which a
baseline MMSE was available, there were 67 deaths that
occurred before a next planned visit: the planning of a next
visit was used to confirm which centenarians were still
alive and who had died. There were 41 confirmed deaths
that occurred before a planned first-year follow-up visit,
and 174 centenarians were confirmed alive at the time of
their first-year follow-up visit. The overall mortality rate in
the first year after inclusion was 0.24 deaths per life-year
(95% CI 0.17–0.32); which relates to a mortality percent-
age of 21% per annual year (95% CI 16–27%). Specifi-
cally, the 106 centenarians who scored C 26 on the MMSE
at baseline had a mortality rate of 0.19 deaths per life-year
(95% CI 0.11–0.29), while the 109 centenarians with
baseline MMSE scores\ 26 had a mortality rate of 0.29
deaths per life-year (95% CI 0.19–0.43) (p = 0.075). Of the
91 centenarians who were eligible for a second follow-up
visit, there were 20 confirmed deaths before this visit, and
71 were confirmed alive at the time of this visit. Therefore,
Table 3 Categorization of vision, hearing and mobility ability
Vision Hearing Mobility
Good Able to read newspapers and watch
television
Able to have and follow a conversation in a group
of people
Able to walk independently (with or
without help of a walking stick or
walker)
Moderate Able to read large texts with large
letters and watch television
Able to have a conversation with one person/
questions do not have to be repeated
Able to walk with help of another
person
Poor Not able to watch television/vision
problems cause some difficulties in
ADL
Limited ability to have a conversation with one
person/questions need to be repeated multiple
times




Limited or complete loss of vision
which causes severe difficulties in
ADL
Not able to have a conversation with one person;
this does not improve when speaking loud and
clearly
Not able to move independently in a
wheelchair
Vision and hearing abilities were estimated while participants used all available devices to support their vision and/or hearing
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Table 4 Categories of conditions analyzed in the GP medical files of 209 centenarians
Condition-category Conditions
Fraction of centenarians with at least one mention of
this condition in their GP report (%)
Fraction of centenarians with a at least one mention of these conditions in their GP
report (%)
Cardiovascular disease (83.7%)
Cardiovascular disease without hypertension (66.5%)
Hypertension (48.8%); congestive heart failure (29.7%); cardiac dysrhythmia (23%);
CVA/TIA (18.7%); angina pectoris (15.3%); myocardial infarction (8.1%); valvular
heart disease (8.1%); thrombosis (6.2%); pacemaker (5.7%); aortic stenosis (2.9%);
amputation leg (1.4%); coronary bypass (1%); hypercholesterolemia (1%); arterial
disease (0.5%); arteritis temporalis (0.5%); atherosclerosis (0.5%); cerebrovascular
insufficiency (0.5%); coronary sclerosis (0.5%); intermittent claudication (0.5%);
orthostatic hypotension (0.5%); pericarditis (0.5%)
Musculoskeletal (63.2%) Arthrosis (35.4%); fractures (34.4%); osteoporosis (14.8%); joint(s) replacement
(11.5%); osteoarthritis (3.3%); hernia (1%)
Vision (41.6%) Cataract (30.1%); macular (7.7%); glaucoma (3.8%); vision impairment (2.4%)
Hearing (30.6%) Hearing impairment (30.6%); cholesteatoma (0.5%); sudden deafness (0.5%)
Cancer (27.8%) Skin cancer (17.2%); breast cancer (4.3%); colon cancer (4.3%); prostate cancer
(1.9%); uterus cancer (1.4%); bladder cancer (0.5%); choleasteatome (0.5%); palate
cancer (0.5%); stomach cancer (0.5%); thyroid cancer (0.5%); vocal chord cancer
(0.5%)
Autoimmunology (22%) Diabetes (7.7%); rheumatoid arthritis (4.8%); hyperthyroidism (3.8%); hypothyroidism
(3.3%); skin cancer (1.4%); asthma (1%); hypopituitarism (0.5%); thyroid
enlargement (0.5%); thyroid removal (0.5%)
Urology (21.5%) UTI (7.2%); incontinence (5.7%); prostate hypertrophy (4.8%); hysterectomy (1.9%);
uterine prolapse (1.9%); catheter (1%); prostate resection hypertrophy (1%); ovarian
cysts (0.5%);
Neurology/psychiatry (15.8%) Balance (3.3%); cognitive decline (2.9%); depression (2.4%); psychiatry (2.4%);
epilepsy (1.9%); delirium (1.4%); insomnia (1%); Parkinson’s (1%); dizziness
(0.5%); migraine (0.5%); tremor (0.5%); WM atrophy (0.5%)
Gastrointestinal (15.3%) Kidney failure (6.7%); gastric ulcer (1.9%); cholecystectomy (1.4%); diverticulosis
(1.4%); gall stones (1.4%); kidney stones (1%); reflux esophagitis (1%);
appendectomy (0.5%); intestinal polyps (0.5%); pancreatitis (0.5%); rectal prolapse
(0.5%); sigmoid resection (0.5%)
Lung disease (10.5%) Pneumonia (6.2%); COPD (2.4%); TBC (1.9%); Emphysema (0.5%); ulcer (0.5%)
Other Erysipelas (1.4%); anemia (1%); herpes zoster (1%); other (1%); restless legs (1%);
eye infection (0.5%); itching (0.5%); pes equinus (0.5%); vitamin B deficiency
(0.5%); vitiligo (0.5%)
Left column: when multiple conditions that belong to one condition-category are mentioned more than once in the GP report of a centenarian,
they are counted as one. Right column: all conditions are counted separately, even though they belong to one condition-category. In aggregate,


























siblings (n) cen-siblings (n) siblings (n) siblings (n) motherfathersiblings (n) cen-sibling
partner
Fig. 3 Data collection from centenarians and their family-members:
In Phase-2 of the 100-plus Study (since September 2017), we obtain
blood-samples from centenarians (black), and when willing, their
siblings, their children (dark grey) and their respective partners (light
grey). We will inquire about longevity and incidence of dementia in
relatives from the same generation as the centenarian (white). Square:
male, circle: female, diamond: both genders are possible
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in the second year after baseline, the mortality rate
increased to 0.32 deaths per life-year (95% CI 0.20–0.49);
which relates to a mortality percentage of 28% per annual-
year (95% CI 18–39%). Specifically, the mortality rate of
the centenarians who scored C 26 points at baseline
remained at a low 0.19 deaths per life-year (95% CI
0.08–0.37), while the mortality rate of centenarians who
scored\ 26 points increased to 0.54 deaths per life-year
(95% CI 0.29–0.90) (p = 3.0 9 10-3) (Fig. 5c). Mortality
rates and related mortality percentages are presented in
Table 4.
Education
We compared centenarian-education levels with individu-
als from the same birth cohort (1912–1916): 55–59 year-
olds as reported in the Dutch population in the 1971 census
[39]. Both centenarian-males and females attained signifi-
cantly higher levels of education compared to their birth
cohort in the 1971 census [33] (p\ 1 9 10-5, Mann–
Whitney U test) (ESM.pdf Fig S4A). Specifically, 79% of
the centenarian males and 66% of the centenarian females
attained more than basic education, compared to respec-
tively 45% and 31% of the males and females in their birth
cohort (Table 5). Workers and self-employed persons with
little education were overrepresented in the * 20% non-
responders in the 1971 census, suggesting that this is a
conservative estimate of the differences [33].
Socio-economic background and status
Based on paternal professions, centenarian—socio-eco-
nomic background (SEB) was compared to 2815 individ-
uals born between 1910 and 1915 from the Historical
Sample of the Netherlands (HSN) [40] (p\ 1 9 10-5,
Mann–Whitney U test) (ESM.pdf Fig S4B-left). Cente-
narian-fathers were threefold more likely to have an elite-
upper middle class occupation and[ 3-fold less likely to
be an unskilled worker compared to their birth cohort.
Based on the professions of the 219 centenarian-males and
centenarian-female-partners, centenarians themselves
attained a significantly higher SES than the 408 males from
the HSN sample born between 1910 and 1919
(p\ 1 9 10-5, Mann–Whitney U test). Centenarians
were[ 4-fold more likely to be elite-upper middle
class,[ 2-fold more likely to be farmers, and[ 3-fold less
likely to be unskilled or farm workers (ESM.pdf Fig S4B-
right). There was no difference between the socio-
Excluded 
• not interested: n=135 (29%) 
• not cognitively healthy: n=122 (27%)  
• considered participation too stressful: n=72 (16%) 
• unknown reasons: n=71 (15%) 
• no longer alive: n=50 (11%),  
• did not agree to donation of a blood sample: n=10 (2%) 
Baseline (T0) inclusion: n=300 
 dd. June 21, 2017
• Data incomplete: n=4 
T1 follow-up (12 months): 170 
Visited n=140, Not available*: n=30 
T2 follow-up (24 months): 67
Visited n=48, Not available*: n=19 
T3 follow-up (36 months): 17
Visited: 11, Not available*: n=6 
• Not eligible for T1 follow-up yet#: n=77 
• Died: n=53 
• Not eligible for T2 follow-up yet#: n=68 
• Died: n=35 
• Not eligible for T3 follow-up yet#: n=36 
• Died: n=14 




Fig. 4 Flowchart of study inclusion: *Not available: centenarians
were on vacation, not interested or too frail for a follow-up visit.
When possible, follow-up was performed by telephone and/or
informant questionnaires. In several cases, centenarians were
available for follow-up one year later, such that this ‘unavailable’
group was formally kept in the study until death. #Not eligible:
centenarians were not yet included in the study long enough to be
eligible for the next follow-up visit
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Table 5 Descriptive statistics of 100-plus Study cohort
Cohort statistics
100-plus cohort, June 2017 (N available, %) 300
Age at inclusion (mean, SD) 101.3 ± 1.7
Birth years (median, IQR) 1914 (1913–1915)
Brain donors (n, %) 81 (27%)
Follow-up visits
T0 baseline visits 300
T1 possible visits (visited, died, missed) 223 (140, 53, 30)
T2 possible visits (visited, died, missed) 155 (48, 88, 19)
T3 possible visits (visited, died, missed) 119 (11, 102, 6)
Mortality
Whole cohort T0–T1 T1–T2
Mortality rate (95% CI) 0.24 (0.17–0.32) 0.32 (0.20–0.49)
Mortality percentage (95% CI) 21% (16–27%) 28% (18–39%)
MMSE < 26 at baseline (95% CI)
Mortality rate (95% CI) 0.29 (0.19–0.43) 0.54 (0.29–0.90)
Mortality percentage (95% CI) 25% (17–35%) 42% (25–59%)
MMSE ‡ 26 at baseline (95% CI)
Mortality rate (95% CI) 0.19 (0.11–0.29) 0.19 (0.08–0.37)
Mortality percentage (95% CI) 17% (10–25%) 17% (8–31%)
Cognitive functioning at baseline
Mini Mental State Examination (MMSE)
100-plus cohort (median MMSE, IQR) 25 (22.0–27.5)
MMSE[ 22a (fraction of cohort, %) 72.4%
MMSE C 26 (fraction of cohort, %) 47.2%
Estimated by trained researcher (n = 287)
Cognitively healthy (fraction of cohort, %; median MMSE (IQR) 83%; 26 (23.5–28.0)
Doubt 14%; 19 (16.4–22.0)
Cognitively impaired 2.8%; 16.4 (12.8–17)
Baseline presentation
Geriatric impairments




Number of comorbidities (avg ± SD) 3.7 ± 1.5
Geriatric depression scale: B 5 (no depression) 91.5%
Living independence
Community dwelling/private residence with care available 51.9%
Private quarters in residential care center 42.0%
Independence in Activities of Daily Living (Barthel Index)
Needs minimal assistance (15–19) 45.1%
Fully independent (20) 32.4%
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economic status (SES) attained as adults of 81 male cen-
tenarians and the male-partners of 138 female-centenarians
(p = 0.22, Mann–Whitney U test).
Smoking behavior and alcohol consumption
Retrospective comparison of smoking behavior suggests that
centenarians smoked less than a representative sample of
Dutch individuals born between 1909 and 1923, as indicated
in a 1958 survey [41, 42]. Of the centenarian-males, 67%
indicated to have smoked regularly or often during an
extended period in their lives, while in 1958, 91% of the
birth cohort males reported to smoke. Of the centenarian
females, 15% indicated to have smoked regularly or often
while 32% of the birth cohort females smoked. Alcohol
consumption was common among centenarians: only 11%
of the centenarian-males and 22% of the centenarian-fe-
males indicated to never consume alcohol, similar to 14% of
male-abstainers and 21.8% female-abstainers among the
birth cohorts in the 1958 survey [41]. In fact, 54% of the
centenarian-males and 31% of the centenarian-females
indicated to consume alcohol regularly or often.
Marriage and children
Centenarians had on average 3.9 ± 2.2 children, which
was more than the average 3.5 ± 2.5 children from 860
Dutch parents born between 1910 and 1915 [43] (p = 0.03,
Mann–Whitney U) (ESM.pdf Fig S4C). However, we
cannot exclude that lifestyle differences (i.e. religious or
regional customs) might confound this increased fertility.










Education > basic (primary school) Centenarians versus populationb, c
Males 79 versus 45%
Females 66 versus 31%
Socioeconomic status
SEB: Social class father: C lower-middle class 31.2 versus 17.9%
SES: Social class-centenarian or –partner: C lower-middle class 55.5 versus 29.4%
Number of children parented: (mean – SD) 3.9 ± 2.2 versus 3.5 ± 2.5
APOE genotypes
APOE genotypes Genotype frequency (%); centenarians versus populationd Odds ratio (95% CI); p valuee
e2/e2 0.9 versus 0.7% 1.30 (0.3–5.7); p = 9.6 9 10-1
e2/e3 24.9 versus 11.7% 2.49 (1.8–3.5); p = 3.4 9 10-7
e2/e4 4.8 versus 3.0% 1.63 (0.8–3.1); p = 2.1 9 10-1
e3/e3 60.3 versus 60.5% 0.99 (0.8–3.1); p = 8.9 9 10-1
e3/e4 8.7 versus 21.3% 0.35 (0.2–0.6); p = 5.7 9 10-7
e4/e4 0.4 versus 2.9% 0.15 (0.0–1.1); p = 3.2 9 10-3
APOE alleles
e2 17 versus 10.7% 2.1 (1.6–2.8); p = 4.8 9 10-7
e3 86.1 versus 87.1% 1.0 (0.8–1.3); p = 1.0
e4 3.2 versus 7.5% 0.44 (0.31–0.63); p = 6.3 9 10-7
aAn MMSE[ 22 is the suggested cutoff score for cognitive health in elderly aged 97 years and above [117], b Centenarian education levels were
compared with 54–61 years olds reported in the Dutch population in the 1971 census [39], c Socio-economic background was compared with
2815 individuals born between 1910 and 1915 from the Historical Sample of the Netherlands (HSN) [40], d APOE genotypes were compared
with 2233 * 50–80-year olds from the Longitudinal Aging Study Amsterdam (LASA) [45], e p values were calculated using a two-sided
Fisher’s Exact test
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86% had one or more children. Of the centenarian females,
16.5% remained childless (36/219), similar to the 16%
childless females born between 1915 and 1919 [44]. Five
males in the cohort (6%) remained childless (birth cohort
data not available [44]).
APOE allele frequency
APOE was genotyped for 266 centenarians (ESM.pdf Fig
S5). Centenarians were[ 2-fold more likely to carry an
APOE-e2 allele than 2233 Dutch population controls aged
60–80 years [45]. Specifically, centenarians are 2.5-fold
more likely to have the APOE-e2/e3 genotype (Table 5).
In contrast, centenarians are[ 2-fold less likely to carry an
APOE-e4 allele compared to the Dutch population;
specifically, centenarians are 2.8-fold less likely to be
genotyped APOE-e3/e4 and 6.7-fold less likely to have
the APOE-e4/e4 genotype. The allele frequency of the
APOE e3 allele was identical for both cohorts.
Discussion
Here, we present the 100-plus Study cohort of cognitively
healthy centenarians based on the first 300 centenarians
included in the 100-plus Study.
On average, the centenarians in the 100-plus
Study cohort have a high performance
on the MMSE; the large majority is independent
and retained hearing and vision abilities
Our inclusion criteria of ‘‘self-reported cognitive health,
which is confirmed by an informant’’ led to a selection
of centenarians with a relatively high level of overall
cognitive functioning. The cohort scored an average
23.9 ± 4.4 points on the MMSE (raw, unimputed), which
is considerably higher than the averageMMSE score of*17
points, by representative centenarian populations
(16.2 ± 8.8 points, Georgia Centenarian Study [46];
18.7 ± 7.4, Italian centenarians from Rome and surround-
ings [47]; 17.7 ± 8.3 centenarians fromNorthern Italy [48]).
The overall cognitive performance of the 100-plus cohort
participants is similar to ‘‘community-dwelling cognitively
healthy centenarians’’ from the Georgia centenarian Study
[49], and ‘‘cognitively healthy’’ Japanese centenarians, who
respectively scored a mean of 24.8 points and 22.3 ± 3.32
points on the MMSE [50].
Next to their retained cognitive functioning, the large
majority of the centenarians had moderate-good hearing and
vision abilities, they were independently mobile, they
enjoyed a relatively high level of independence in activities
of daily living (ADL), and had no or few symptoms of
depression. Centenarianswere either community dwelling or
lived independently in a residence or in a care center with
available services. Together, these findings underscore that
the 100-plus Study cohort is not a representative population
of Dutch centenarians, rather, it represents a high-perform-
ing, independent sub-selection of Dutch centenarians.
Cognitive performance is associated
with mortality
The mortality in our cohort was 21% per annual year,
which is two-fold lower relative to the centenarians in the
general Dutch population [51]. In the second year after
baseline centenarians with high cognitive functioning at
baseline retained a low mortality rate of 17% per annual-











































































Fig. 5 Overall cognitive functioning (Mini–Mental State Examina-
tion): a Mini–Mental State Examination (MMSE) scores. b Re-
searcher impression of cognitive health at first visit, compared to
MMSE score. c Mortality rate of centenarians with high and low
performance on the MMSE
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baseline had a mortality rate of 42% per annual-year.
These findings confirm that we have succeeded in selecting
the healthiest of the centenarians, as we assume that these
will be maximally enriched with protective (genetic) fac-
tors. Our results further confirm that there is an overlapping
etiology of maintained cognitive and overall health, and
cognitive functioning [52, 53]. The longitudinal set-up of
our study allows us to monitor changes in cognition in
combination with other factors of overall health that occur
between baseline and death to identify to which extent
centenarians escaped or delayed cognitive impairment.
The 100-plus cohort is twofold enriched
with males
The fraction of centenarian-males is 27%, twice the frac-
tion of males (14.4%) in the total Dutch centenarian pop-
ulation on January 1st 2017 [54]. Indeed, since dementia-
prevalence in centenarian populations is consistently lower
in males (* 40%) than in females (* 60%) [55, 56], we
had on forehand expected that our inclusion criteria of
‘‘self-reported cognitive health, which is confirmed by an
informant’’ might lead to a relative enrichment of cente-
narian males in the cohort. Based on the fraction of cen-
tenarian males in the population (14.3% in 2017) and lower
dementia prevalence in males (40 vs. 60%), we estimated
that the fraction of males in the 100-plus Study cohort
should be approximately 20%. This suggests that dementia
incidence does not fully explain the excess of males in our
cohort, which leaves room for, for example, the influence
of a participation bias and a better general well-being of
centenarian males [57].
Disease in male and female centenarians
Despite the cognitive health of the centenarians in the
100-plus Study cohort, they were diagnosed with on average
four morbidities at baseline. Previous studies have shown
that females are more prone to develop chronic nonfatal
conditions such as dementia, arthritis and osteoporosis [58],
while males are more likely to develop fatal conditions, such
as cardiovascular disease and cancer [59, 60]. In agreement
with these studies, we found that the females in the 100-plus
Study cohort had a higher prevalence of musculoskeletal
diseases and hypertension while males had a higher preva-
lence of heart disease and CVA/TIAs.
The 100-plus Study cohort is equally depleted
with the APOE-e4 allele compared to other
centenarian cohorts, but it is strongly enriched
with the neuroprotective APOE-e2 allele
The 100-plus Study cohort was 2.3-fold less likely to carry
the APOE-e4 AD-risk allele compared to their birth cohort
at 60–80-years (OR = 0.44, p = 6.3 9 10-7) [45]. This is
in complete concordance with the depletion of the e4
allele observed in a meta-analysis of 2776 (mostly Cau-
casian) centenarians and 12,000 controls (OR = 0.43,
p\ 1 9 10-3) [61]. It is well established that carrying one
or two APOE-e4 alleles is associated with respectively a
3–5 and 10–30-fold increased risk of developing AD.
Depletion of the APOE-e4 allele in centenarians confirms
that e4 allele carriers dropped out of the population during
aging [62]. On the other hand, carrying one protective
APOE-e2 allele is associated with a two-fold decreased
lifetime risk of developing AD [63, 64]. But the large
centenarian meta-analysis indicated that the protective
aspect of the APOE-e2 allele does not extend to an
enrichment in centenarians (OR = 1.08, p = 0.66),
although weak evidence for an enrichment of the APOE-
e2/e3 genotype was observed (OR = 1.4, p = 1.7 9 10-2)
[61]. In contrast, we find strong evidence for an enrich-
ment of the APOE-e2 allele in cognitively healthy cente-
narians from the 100-plus Study cohort compared to their
birth cohort at 60–80-years: centenarians were 2.1-fold
more likely to carry the APOE-e2 allele (p = 4.8 9 10-7),
and 2.5-fold more likely to have an APOE-e2/e3 genotype
(p = 3.4 9 10-7). This confirms previous suggestive find-
ings in a cohort of Italian centenarians who were free of
dementia or any other major age-related conditions, which
had a similar enrichment of the APOE-e2 allele [65]. We
speculate that this enrichment of the APOE-e2 allele is not
a consequence of our selection of extreme ages, but that it
reflects our selection of individuals with retained (cogni-
tive) health until extreme ages.
The specific enrichment of the APOE-e2 in the cente-
narians with high cognitive performance suggests that the
etiology for reaching 100 years with maintained (cogni-
tive) health may be distinct from the etiology of reaching
100 years in general. Our results indicate that while
searching for (genetic) factors that maintain cognitive
health, the APOE genotype should be taken into account.
Centenarians came, on average, from higher
socio-economic classes and had higher levels
of education
On average, centenarians came from a higher socio-eco-
nomic background than their birth cohort. A high fraction of
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centenarian-fathers were farmers, mostly on their own farm,
a common occupation in the Netherlands during the early
twentieth century. As adults, centenarians attained a higher
socio-economic status and they hadmore children compared
to their birth cohort. Both male- and female-centenarians
attained higher levels of education than the males and
females from their birth cohorts. These findings reflect the
selective survival advantage of individuals from the higher/
middle socioeconomic classes and farmers, during the
majority of the twentieth century in the Netherlands [66].
Together, this is in agreement with results from several
centenarian studies, which showed that socioeconomic
background, educational attainment, and adult socioeco-
nomic status influenced the chance to become a centenarian
[67]. Likewise, having children associates with an increased
chance of reaching extreme ages, likely due to the involve-
ment of children in the care for their aged parent [68].
Alcohol consumption of centenarians was similar
to birth cohort peers, and they smoked—but less
Two-thirds of the centenarian males and 15% of the cen-
tenarian females indicated to have smoked regularly or
often during an extended period in their life. This was less
than their birth cohort peers, of whom almost all males and
a third of the females smoked [41]. Alcohol consumption
of the centenarians was similar to their birth cohorts. These
results are partly in agreement with lifestyle behaviours
from the American Ashkenazi Jewish centenarians, whose
alcohol consumption and smoking behaviour was not dif-
ferent from the general population [69].
Wenote that comparisons of lifestyle habits such as alcohol
consumption and smoking rely on recall of habits from sev-
eral decades ago, which may introduce recall bias. For this
reason, we focused on investigating lifestyle factors that are
manifest for a longer period during a lifetime. Habits that may
be more variable throughout life, such as dietary or exercise
habits,might bemore difficult to recall andwe chose to refrain
from investigating these. Despite these limitations, a within-
cohort analysis of these variables may add to the rich phe-
notypic data available for this cohort.
Conclusions
The 100-plus Study cohort represents cognitively healthy
Dutch centenarians. Compared to their birth cohort peers,
centenarians from this cohort attained significantly higher
levels of education, were from a higher socioeconomic
background, attained higher socioeconomic status, and
they had more children, all of which confirms previous
findings that these factors are associated with the chance of
reaching 100 years in cognitive health. The combined
contributions of these features, which are often
concentrated within families, and the enrichment with the
genetically heritable APOE-e2 allele, will most likely
explain a considerable proportion of the high heritability of
reaching 100 years with maintained cognitive health.
However, these features do not apply to all centenarians,
and only a third of the cohort carries the APOE-e2 allele.
This suggests that additional protective factors may
account for the cohort phenotype.
With the recent developments in biotechnology, novel
findings regarding the physiology of exceptional longevity
and cognitive function are emerging [70, 71]. The avail-
ability of blood and brain tissues from the healthiest cen-
tenarians provides the opportunity to acquire insights in the
molecular constellations associated with the long-term
maintenance of cognitive health. Ultimately, with this
cohort we aim to contribute to the generation of novel
hypotheses regarding the generation of novel therapeutic
targets that offer resilience to cognitive decline.
Acknowledgements We are grateful for the collaborative efforts of all
participating centenarians and their family members and/or relations.
We also want to acknowledge the many people who contributed and
continue to contribute to the study. The students involved in
recruiting and visiting the centenarians: Lieke Jansma, Lieve Steins
Bisschop, Sanne Koole, Sanne Hofman, Anna Kamsteeg, Saiedah
Wekker, Matteo Neumann, and Marlous Jansen. The personnel who
facilitated data collection and storage in available biobanks: Michiel
Kooreman, Annemieke Rozemuller, Jeroen Hoozemans, Hans Gille,
Charlotte Teunissen. The persons who advised on the collection
procedures of specific data: Quinten Waisfisz, Eus van Someren, Ted
Koene, Bart van Berckel, Wiesje van der Flier, Vivi Heine, Erik
Sistermans, Cornelia van Duijn. We thank Marcel Reinders and Sven
van der Lee for critically reviewing the manuscript before submission.
Authors’ contributions HH conceived and designed the study and
wrote the manuscript; NB helped obtain ethical approval for the study
and with the management of communication with participants and
their proxies; TD is dedicated GP and analyzed GP reports, KP, EW,
KS, LT, DB and SR visited the centenarians and helped design/im-
prove the study as it evolved; SS advised on the design of the neu-
ropsychological testing battery; FvP provided expert knowledge on
occupation classification and the demographics of the 1910–1920
birth cohorts, HMH contributed substantive support for study set-up;
MH helped with the study design and manages the Open Clinica
database for data storage; PS contributed substantive support for the
study and aided with obtaining necessary funding. All authors read
and approved the final manuscript.
Funding This work was supported by Stichting Alzheimer Nederland
(WE09.2014-03), Stichting Diorapthe (VSM 14 04 14 02) and
Stichting VUmc Fonds.
Compliance with ethical standards
Conflict of interest The authors declare that they have no conflict of
interests.
Ethics approval and consent to participate The local Medical Ethical
Committee has approved the 100-plus Study (registration number:
2016.440). All procedures performed in studies involving human
The 100-plus Study of cognitively healthy centenarians: rationale, design and cohort… 1243
123
participants were in accordance with the ethical standards of the insti-
tutional and/or national research committee and with the 1964 Helsinki
declaration and its later amendments or comparable ethical standards.
Informed consent Informed consent was obtained from all individual
participants included in the study.
Open Access This article is distributed under the terms of the Creative
Commons Attribution 4.0 International License (http://creative
commons.org/licenses/by/4.0/), which permits unrestricted use, distri-
bution, and reproduction in anymedium, provided you give appropriate
credit to the original author(s) and the source, provide a link to the
Creative Commons license, and indicate if changes were made.
Box: Study rationale
The design of an intervention for neurodegenerative diseases
requires not only the understanding of the neurodegenerative
processes involved, but also a deep comprehension of the
processes thatmaintain cognitive health during ageing. Although
increasing age is the strongest predictive factor for cognitive
decline and dementia, some people live to be over 110 years in
great mental health. A Dutch woman, Hendrikje van Andel-
Schipper (1890–2005), reached the age of 115 with full cognitive
abilities [3] and showed that it is possible to reach extreme ages
without any symptoms of cognitive decline. Her remarkable case
became the source of inspiration for the initiation of the 100-plus
Study at theAlzheimerCenterAmsterdam in2013.To investigate
the physiology of her extended cognitive health, it is necessary to
compare her clinical characteristics with those from other
individuals with the same extraordinary combination of
phenotypes: extremely old and cognitively healthy. Below, we
provide a rationale for researching protective factors against
cognitive decline in cognitively healthy centenarians, based on
the mortality rate and dementia incidence in their birth cohort
during its process of aging.
_____
The number of centenarians in the Netherlands is growing
quickly: on January 1st 2013 there were 1940 centenarians in
the Netherlands, which grew to 2225 centenarians on January
1st 2017, and this number is expected to rise to 5000 by 2035
[54]. Of the individuals born between 1910 and 1915,
approximately 1:160 (0.6%) have reached ages C 100 years
[72]. Since 25–30% of all centenarians are estimated to be free
of symptoms of cognitive decline [74–76], becoming a
centenarian with retained cognitive health was reserved for
only 0.2–0.3% of the 1910 and 1915 birth generation.
Almost all participants of the 100-plus Study cohort were born
in the Netherlands just before or during WWI (1914 and
1917), in which the Netherlands was neutral. The 20th century
in the Netherlands was further characterized by a depression
in the thirties, WWII between 1940 and 1945, a post-war
period typified by a rebuilding phase in the 1950s and a
continuous increase in prosperity, health care improvements
and technological developments. According to the Human
Mortality Database [72] males born in the Netherlands
between 1910 and 1915 had a mean lifespan of 58.7 years and
females had a mean lifespan of 66.1 years.
Here we describe the 1910–1915 birth cohort by their mortality
rates and dementia incidence from birth to[ 100 years (Box-
Figure). For this, we prefer presenting the instant mortality
rate over the mortality percentage, because, while estimates are
similar at younger ages, the mortality percentage
underestimates the mortality at extreme ages (for further
explanation see Mortality estimations in ESM.pdf). For ages
0–60 years, we represent mortality rate by age from
individuals born in 1912, and for ages[ 60 years we
represent mortality rates using combined statistics from the
1910–1915 birth cohorts.
(A) In 1912, 170,000 babies were born, and they were exposed
to a mortality rate of close to 0.10 deaths life-year (* 10%
per annual-year) during their first year of life, reflecting
prevalent childhood diseases. (B) In 1918, the Spanish Flu
made[ 40,000 casualties in the Netherlands [77], which was
especially lethal among 20–40 year olds [78]. The Spanish
Flu increased mortality among the 1912-born six-year olds by
twofold. (C) At age 10, most childhood diseases were
overcome and the mortality rate reached a
stable * 0.001–0.002 deaths per life-year (* 0.10–0.20%
per annual-year), caused by incidental deaths (i.e. fatal
accidents, drowning etc. (D) When the 1912 birth cohort was
28 years, the onset of WWII in 1940 led to a peak in male
mortality. (E) The ensuing Hunger Winter in 1945 led to a
second mortality peak when the 1912 birth cohort was
33 years old, more so in males than in females. (F) When the
cohort was 40 years old, the mortality resulting from natural
decline rose above the rate of incidental deaths, and increased
in the log scale according to Gompertz Law (1825) [79].
(G) During natural decline of the 1912 birth cohort, the males
had a higher mortality rate than females, and this mortality
gender gap ultimately resulted in a 1:7 male/female ratio at
age 100 [54]. Approximately 70% of the mortality gender gap
in these cohorts can be explained by the difference in smoking
behavior between males and females [80]: an estimated 91%
of all males born in 1912 smoked while only 30% of the
females smoked, which ultimately led to a relative increased
incidence of fatal smoking-related diseases in males. The
remainder of the mortality gender gap may be explained by
biological or environmental differences between males and
females [81]. (H) At 100 years old, the 1912 cohort has
reduced to ± 1000 persons and the instant mortality rate for
both males and females is at 0.5 deaths per life-year (which
translates to a mortality percentage of * 40% per annual-
year).
(I) Individuals from the 1910–1915 birth cohorts were exposed
to an increasing incidence of overall dementia from age
60 years onwards, of which the greatest proportion was
(J) Alzheimer’s Dementia (AD) [1]. At approximately
100 years, the instant incidence of dementia reaches 0.5 cases
per dementia-free year, which translates to a dementia
proportion of * 40% per annual-year. At this age, the
dementia incidence surpasses the mortality rate per year,
suggesting that after turning 100 years, a centenarian is
exposed to greater odds of developing dementia than to die
[6]. (K1) If dementia incidence after 100 years continues to
increase exponentially, following the Gompertz law of natural
decline [79], then a conservative estimation of dementia
incidence (by concentrating mortality on incident dementia
cases) suggests that all individuals who reach 108–110 years
would have to be demented. (K2) In contrast, reports of
individuals who are older than 110 years indicate that the
majority of such individuals has, in fact, retained their
cognitive health [3–5]. Therefore, it is likely that the incidence
of dementia decelerates or even declines at extreme ages [6].
Although the slope of the incidence rate suggested by Corrada
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et al. (red dots in Box-Figure) is slightly smaller compared to
the extrapolated incidence (dashed line), there currently is no
clear evidence for this deceleration between 90 and 100 years
[2, 82], it is most likely that this deceleration becomes evident
somewhere after 100 years. This is consistent with findings in
super-centenarians by Andersen et al. [5], who demonstrated
the progressive compression of both disability and morbidity
(in 6 diseases including dementia) with survival beyond
100 years. Furthermore, in a recent study based on data from
3836 centenarians in Italy, Barbi et al. found that mortality
decelerates, and even plateaus, above age 105 [83]. Together,
this suggests that factors that preserve (cognitive) health may
be progressively enriched for during healthy aging [7],
providing a window of opportunity to search for such
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Box-Figure: Instant mortality and dementia rates in centenarian
birth cohort. Blue line: Male mortality. Shades of blue represent
confidence intervals (CI) on the mortality rate by 10-percentile
increments [84]; for ages 0–59 years we used only the mortality
statistics of individuals born in 1912 (as to avoid blurring specific
mortality peaks), and for ages 60–100 years we combined statistics
of the 1910–1915 birth cohorts, which reduced CIs. Mortality after
age 100 years was extrapolated in accordance with the Gompertz’
law of mortality [85]. Purple line: Female mortality with CIs [84].
Red line: Median incidence of overall dementia with CIs for age
groups 55–59, 60–64, 65–65, 70–74, 75–79, 80–84, 85–89 years [1].
To define mean age per age-group, we assumed that the ages of the
individuals that constituted each age-group were distributed accord-
ing to associated mortality statistics. Red dots: Dementia incidence
for age groups: 90–94 years (mean age 92.7), 95–99 years (mean age
96.4) and 100 ? (mean age 101.3) [2]. Green line: Alzheimer’s
Disease (AD) incidence with CIs [1]. Dashed red line: extrapolation
of dementia incidence according to its exponential increase. To
extrapolate dementia incidence, we fitted a Gompertz curve on
available dementia incidence data [1, 2]. For the reported age ranges
we compared the estimated dementia incidence with the reported
incidence through a binomial distribution. This resulted in a log-
likelihood, which was optimized (see ESM.pdf for mortality
calculations)
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